File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Interleukin 13 participates in terminal differentiation of esophageal squamous cell carcinoma cells

TitleInterleukin 13 participates in terminal differentiation of esophageal squamous cell carcinoma cells
Authors
Issue Date1-Aug-2022
PublisherAME Publishing
Citation
Journal of Gastrointestinal Oncology, 2022, v. 13, n. 4, p. 1571-1578 How to Cite?
Abstract

Background: In China, esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of all esophageal cancer cases. Interleukin 13 (IL-13) was widely reported to play a key role in tumor progression. Our previous study reported that IL-13 was a favorable predictive marker for the overall survival of esophageal squamous cell carcinoma (ESCC) patients, but how IL-13 contributes to ESCC progression remains unknown. This study aims to explore the role of IL-13 and its underlying downstream molecular mechanisms in ESCC progression.

Methods: Tissue microarrays including 262 primary ESCC tumor tissues were collected and analyzed. The expression of IL-13 in ESCC tumor tissue was detected with immunohistochemistry staining (IHC). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to qualify the expressions of KRT13KRT4 and 15-lipoxygenase-1 (15-LOX-1) in cultured ESCC cell lines with recombinant IL-13 treatment.

Results: IL-13 was expressed in the esophageal epithelium cells and ESCC tumor cells. High IL-13 expression in ESCC tumor cells predicted a good prognosis for patients. Recombinant human IL-13 raised KRT13 and 15-LOX-1 mRNA levels, but lowered KRT4 mRNA level 15-LOX-1 in ESCC cells in vitro.

Conclusions: In summary, our study suggests that IL-13 might improve the prognosis of ESCC by promoting the terminal differentiation of ESCC cells. This may offer potential new therapeutic target for early treatment of ESCC.


Persistent Identifierhttp://hdl.handle.net/10722/328537
ISSN
2023 Impact Factor: 2.0
2023 SCImago Journal Rankings: 0.600
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, J-
dc.contributor.authorWang, WW-
dc.contributor.authorWang, K-
dc.contributor.authorMa, GW-
dc.contributor.authorShao, J-
dc.contributor.authorFang, WZ-
dc.contributor.authorZhou, YT-
dc.contributor.authorLin, JT-
dc.contributor.authorGuo, YB-
dc.contributor.authorGuan, XY-
dc.contributor.authorDuan, CH -
dc.date.accessioned2023-06-28T04:45:56Z-
dc.date.available2023-06-28T04:45:56Z-
dc.date.issued2022-08-01-
dc.identifier.citationJournal of Gastrointestinal Oncology, 2022, v. 13, n. 4, p. 1571-1578-
dc.identifier.issn2078-6891-
dc.identifier.urihttp://hdl.handle.net/10722/328537-
dc.description.abstract<p><strong>Background: </strong>In China, esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of all esophageal cancer cases. Interleukin 13 (IL-13) was widely reported to play a key role in tumor progression. Our previous study reported that IL-13 was a favorable predictive marker for the overall survival of esophageal squamous cell carcinoma (ESCC) patients, but how IL-13 contributes to ESCC progression remains unknown. This study aims to explore the role of IL-13 and its underlying downstream molecular mechanisms in ESCC progression.</p><p><strong>Methods: </strong>Tissue microarrays including 262 primary ESCC tumor tissues were collected and analyzed. The expression of IL-13 in ESCC tumor tissue was detected with immunohistochemistry staining (IHC). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to qualify the expressions of <em>KRT13</em>, <em>KRT4</em> and 15-lipoxygenase-1 (<em>15-LOX-1</em>) in cultured ESCC cell lines with recombinant IL-13 treatment.</p><p><strong>Results: </strong>IL-13 was expressed in the esophageal epithelium cells and ESCC tumor cells. High IL-13 expression in ESCC tumor cells predicted a good prognosis for patients. Recombinant human IL-13 raised <em>KRT13</em> and <em>15-LOX-1</em> mRNA levels, but lowered <em>KRT4</em> mRNA level 15-LOX-1 in ESCC cells <em>in vitro</em>.</p><p><strong>Conclusions: </strong>In summary, our study suggests that IL-13 might improve the prognosis of ESCC by promoting the terminal differentiation of ESCC cells. This may offer potential new therapeutic target for early treatment of ESCC.</p>-
dc.languageeng-
dc.publisherAME Publishing-
dc.relation.ispartofJournal of Gastrointestinal Oncology-
dc.titleInterleukin 13 participates in terminal differentiation of esophageal squamous cell carcinoma cells-
dc.typeArticle-
dc.identifier.doi10.21037/jgo-22-559-
dc.identifier.hkuros344661-
dc.identifier.volume13-
dc.identifier.issue4-
dc.identifier.spage1571-
dc.identifier.epage1578-
dc.identifier.eissn2219-679X-
dc.identifier.isiWOS:000845018600001-
dc.identifier.issnl2078-6891-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats